Keywords: Novartis, Vectura, Sosei, COPD, NVA237

Novartis COPD drug candidate NVA237 superior to placebo and similar to tiotropium in Ph III

Article | 01 July 2011

Print This

Swiss drug major Novartis (NOVN: VX) has announced positive results from the pivotal Phase III GLOW2 clinical trial showing that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in